Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment

Bone

Volumn 40, Issue 3, 2007, Pages 638-644

  Land, Christof ^a   Rauch, Frank ^a   Travers, Rose ^a   Glorieux, Francis H ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Children; Fractures; Gross motor function; Osteogenesis imperfecta; Osteoporosis; Pamidronate

Indexed keywords

ANTIPYRETIC AGENT; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEVER; FLU LIKE SYNDROME; FRACTURE; HUMAN; LUMBAR SPINE; MORPHOMETRICS; OSTEOGENESIS IMPERFECTA; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

EID: 33846592746     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.10.010     Document Type: Article

References (18)

1. Glorieux F.H., Ward L.M., Rauch F., Lalic L., Roughley P.J., and Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J. Bone Miner. Res. 17 (2002) 30-38
2. Rauch F., and Glorieux F.H. Osteogenesis imperfecta. Lancet 363 (2004) 1377-1385
3. D'Amour P., Labelle F., Lecavalier L., Plourde V., and Harvey D. Influence of serum Ca concentration on circulating molecular forms of PTH in three species. Am. J. Physiol. 251 (1986) E680-E687
4. Bollen A.M., and Eyre D.R. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 15 (1994) 31-34
5. Land C., Rauch F., Munns C.F., Sahebjam S., and Glorieux F.H. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39 (2006) 901-906
6. Eastell R., Cedel S.L., Wahner H.W., Riggs B.L., and Melton III L.J. Classification of vertebral fractures. J. Bone Miner. Res. 6 (1991) 207-215
7. Salle B.L., Braillon P., Glorieux F.H., Brunet J., Cavero E., and Meunier P.J. Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr. 81 (1992) 953-958
8. Ogden C.L., Kuczmarski R.J., Flegal K.M., Mei Z., Guo S., Wei R., et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109 (2002) 45-60
9. Rauch F., Neu C.M., Wassmer G., Beck B., Rieger-Wettengl G., Rietschel E., et al. Muscle analysis by measurement of maximal isometric grip force: new reference data and clinical applications in pediatrics. Pediatr. Res. 51 (2002) 505-510
10. Bleck E.E. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin. Orthop. Relat. Res. (1981) 111-122
11. Haley S.M., Coster W.J., Ludlow L.H., Haltiwanger J.T., and Anrellos P.J. Pediatric Evaluation of Disability Inventory (PEDI): development, standardization and administrative manual (1992), New England Medical Center, Boston
12. Glorieux F.H., Travers R., Taylor A., Bowen J.R., Rauch F., Norman M., et al. Normative data for iliac bone histomorphometry in growing children. Bone 26 (2000) 103-109
13. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
14. Weber M., Roschger P., Fratzl-Zelman N., Schoberl T., Rauch F., Glorieux F.H., et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39 (2006) 616-622
15. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., and Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339 (1998) 947-952
16. Astrom E., and Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child. 86 (2002) 356-364
17. Rauch F., Plotkin H., Travers R., Zeitlin L., and Glorieux F.H. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J. Clin. Endocrinol. Metab. 88 (2003) 986-992
18. Zeitlin L., Rauch F., Travers R., Munns C., and Glorieux F.H. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Bone 38 (2006) 13-20